Scarica l'app Stockscreener
1.60
6.98%
-0.12
Autolus Therapeutics Plc Adr Borsa (AUTL) Ultime notizie
Autolus Therapeutics (NasdaqGS:AUTL) Stock Forecast & Analyst Predictions - Simply Wall Street
Autolus Therapeutics Executive Reports RSU Vesting and Share Sale in Form 4 Filing - Kalkine Media
Autolus Therapeutics (AUTL) insider reports 20,000 RSUs - Stock Titan
Autolus (NASDAQ: AUTL) holder plans ADS sale tied to tax on vested stock - Stock Titan
Autolus Therapeutics (NASDAQ:AUTL) Sets New 1-Year HighStill a Buy? - MarketBeat
Alphabet Inc. Takes Position in Autolus Therapeutics PLC Sponsored ADR $AUTL - MarketBeat
Autolus Therapeutics (NASDAQ:AUTL) Trading 6.3% HigherStill a Buy? - MarketBeat
Syncona Portfolio Ltd Buys Shares of 16,640,720 Autolus Therapeutics PLC Sponsored ADR $AUTL - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Autolus Therapeutics (AUTL): Armistice Capital discloses 15M-share, 5.64% ADS stake - Stock Titan
Autolus Therapeutics plc (AUTL) Stock Price, News, Quote & History - Yahoo Finance
Autolus Therapeutics (NASDAQ:AUTL) Trading Down 7%Here's Why - MarketBeat
Autolus Therapeutics (NASDAQ:AUTL) Trading 13.3% Higher Following Strong Earnings - MarketBeat
Renaissance Technologies LLC Has $3.17 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL - marketbeat.com
Autolus Secures New $250 Million Financing and Warrants - The Globe and Mail
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap UpStill a Buy? - MarketBeat
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors - The Manila Times
AUTL Q1 2026 Earnings: EPS Misses Consensus by 2.94% as CAR-T Commercial Buildout Continues - dars.gov.et
AUTL Q1 2026 Earnings: EPS Misses Consensus by 2.94% as CAR-T Commercial Buildout ContinuesRevenue Breakdown Analysis - dars.gov.et
AUTL Q1 2026 Earnings: EPS Misses Consensus by 2.94% as CAR-T Commercial Buildout ContinuesShare Dilution Risk - www.dars.gov.et
AUTL Q1 2026 Earnings: EPS Misses Consensus by 2.94% as CAR-T Commercial Buildout ContinuesEPS Consistency Score - dars.gov.et
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Autolus Therapeutics (NASDAQ:AUTL) Trading Down 0.7%Time to Sell? - MarketBeat
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Autolus awards stock grants to 13 new employees - Stock Titan
AUTLAutolus Therapeutics plc ADR Options - Finviz
Autolus Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:AUTL) - TradingView
Enterprise value to revenue forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Price to book forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Price to sales forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Price to earnings forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Enterprise value to EBITDA forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Autolus Therapeutics (AUTL) could find a support soon, here's why you should buy the stock now - MSN
Autolus Therapeutics (AUTL) could find a support soon, here's why you should buy the stock now - MSN
Autolus Therapeutics (AUTL) could find a support soon, here's why you should buy the stock now - MSN
Autolus Therapeutics Receives Prix Galien UK Award - GlobeNewswire Inc.
Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Autolus Therapeutics releases annual report and schedules shareholder meeting - Investing.com
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy? - sharewise.com
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy? - Zacks Investment Research
Autolus Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.
AUTL - Finviz
Apellis Pharmaceuticals (APLS) moves 135.4% higher: Will this strength last? - MSN
Apellis Pharmaceuticals (APLS) moves 135.4% higher: Will this strength last? - MSN
Autolus Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Autolus Therapeutics (NASDAQ: AUTL) to cut 13% of staff, save $15M - Stock Titan
Autolus Therapeutics Eyes CAR-T Edge With AUCATZYL Safety, Expands Centers, Sees Margin Turnaround - Yahoo Finance
Autolus Therapeutics (NASDAQ: AUTL) registers $150M shelf for shares, ADSs, debt - Stock Titan
Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data - Yahoo Finance
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):